ICE Bioscience Posters

Download

Obesity is a significant chronic disease that currently impacts approximately 40% of the global population, with projections from the World Obesity Atlas (WOA)1 indicating this figure could exceed 50% by 2035. Like other chronic conditions, obesity necessitates ongoing, lifelong management. Historically, long-term treatment out-comes for obesity have been disappointing and the challenges for obesity drug discovery include inefficient in vitro systems to evaluate multi-pathway interventions. Our comprehensive platform accelerates GPCR drug discovery by integrating High-throughput screening (HTS) in cell-based assay (reporter assay, HTRF cAMP, β-recruitment), supporting hit finding, balanced or biased compound (small molecular, peptides, antibody) test.